Orion Oyj (HEL:ORNAV)

Market Cap	7.68B
Revenue (ttm)	1.54B
Net Income (ttm)	329.90M
Shares Out	n/a
EPS (ttm)	2.35
PE Ratio	23.29
Forward PE	n/a
Dividend	1.63 (3.01%)
Ex-Dividend Date	Apr 4, 2025

Volume	4,659
Average Volume	7,305
Open	54.30
Previous Close	54.20
Day's Range	53.50 - 54.30
52-Week Range	32.50 - 56.90
Beta	0.35
RSI	50.86
Earnings Date	Apr 23, 2025

About Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Trexan for rheumatoid art...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1917
• Employees: 3,880
• Stock Exchange: Nasdaq Helsinki
• Ticker Symbol: ORNAV

Financial Performance

In 2024, Orion Oyj's revenue was 1.54 billion, an increase of 29.65% compared to the previous year's 1.19 billion. Earnings were 329.90 million, an increase of 52.17%.